Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Double-blind, Randomised, 5-arm, Vehicle-controlled, Dose-ranging Trial to Evaluate the Efficacy and Safety of Twice Daily Topical Application of Delgocitinib Cream 1, 3, 8, and 20 mg/g for 16 Weeks in Adult Subjects With Mild to Severe Chronic Hand Eczema

NCT03683719 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT03683719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03683719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Double-blind, Randomised, 5-arm, Vehicle-controlled, Dose-ranging Trial to Evaluate the Efficacy and Safety of Twice Daily Topical Application of Delgocitinib Cream 1, 3, 8, and 20 mg/g for 16 Weeks in Adult Subjects With Mild to Severe Chronic Hand Eczema
Lead sponsor
LEO Pharma
Phase
Phase 2
Overall status
Completed
Start date
November 28, 2018
Completion date
April 20, 2020
Enrollment
258 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hand eczema